| Entry |
|
|---|
| Name |
Yttrium Y 90 epratuzumab tetraxetan (USAN) |
|---|
| Efficacy |
Antineoplastic, Radioactive agent, Anti-CD22 antibody |
|---|
| Type |
Antibody-drug conjugate |
|---|
| Comment |
Radioimmunotherapy (RAIT) for non-Hodgkin's B-cell lymphoma
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04662 | B cell receptor signaling pathway |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: Ig superfamiy
SIGLEC family
CD22 (SIGLEC2)
D06349 Yttrium Y 90 epratuzumab tetraxetan (USAN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
